Reuters logo
BRIEF-Amgen presents new data from phase 3 xgeva study in multiple myeloma patients
March 3, 2017 / 9:53 PM / 7 months ago

BRIEF-Amgen presents new data from phase 3 xgeva study in multiple myeloma patients

March 3 (Reuters) - Amgen Inc

* Amgen presents new data from phase 3 xgeva® (denosumab) study in multiple myeloma patients at the 16th international myeloma workshop

* Amgen inc says positive data from phase 3 ‘482 study

* Amgen -secondary endpoints of superiority in delaying time to first sre and delaying time to first-and-subsequent sre were not met in this study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below